The European Union (EU) has granted a CE mark certification to Medi-tate's benign prostate hyperplasia (BPH) device.

The BPH device is a minimally invasive procedure which is designed to reshape the urethra, reports.

Medi-tate provides solution to patients and urologists, achieving surgery-like results using a minimally invasive office procedure and avoiding traumatic tissue cutting, heavy sedation and hospitalization.

Medi-tate said 5 million American men have BPH symptom, only one fifth of whom are treated, and one tenth of them by surgery.